Drug Trial Radar · NCT06280391
A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis
Last checked: Nov 19, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
314
Actual
Start
Feb 20, 2024
Primary completion
Sep 16, 2025
Study completion Feb 2, 2026
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- Collaborators
- Regeneron Pharmaceuticals
- First posted
- Feb 28, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
ACT18018 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 2 study with 3 treatment groups. The purpose of this study was to evaluate efficacy, safety and tolerability with 2 dosing regimens of itepekimab compared with placebo in male and/or female participants with NCFB aged 18 years of age up to 85 years of age (inclusive). Study details include: * The study duration (screening, 24-52-week treatment, 20-week safety follow-up) was up to 47-77 weeks * The treatment duration was up to 24-52 weeks * The follow-up duration was 20 weeks * Site/phone visits were at a monthly interval
Conditions
- Bronchiectasis
Interventions
Itepekimab (SAR440340)Drug
* Pharmaceutical form: solution for injection in pre-filled syringe * Route of administration: subcutaneous
PlaceboDrug
* Pharmaceutical form: solution for injection in pre-filled syringe * Route of administration: subcutaneous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Rate of Adjudicated Moderate or Severe Pulmonary Exacerbations (PEs) Over the Treatment PeriodTime frame: Baseline (Day 1) up to Week 24 to 52
Locations
117 sites in 20 countries. Site status is shown where the registry gives one.
Pulmonary Associates - Phoenix - East McDowell Road- Site Number : 8400012
Phoenix, Arizona
Southern California Institute for Respiratory Diseases- Site Number : 8400002
Los Angeles, California
Allianz Research Institute- Site Number : 8400013
Westminster, California
Allianz Research Institute CO- Site Number : 8400038
Aurora, Colorado
University of Connecticut Health Center- Site Number : 8400020
Farmington, Connecticut
Yale New Haven Hospital- Site Number : 8400065
New Haven, Connecticut
Advanced Pulmonary Research Institute- Site Number : 8400007
Loxahatchee Groves, Florida
High Quality Research- Site Number : 8400047
Miami, Florida
Avanza Medical Research Center- Site Number : 8400018
Pensacola, Florida
Private Practice - Dr. Frank Hull - Plantation- Site Number : 8400010
Plantation, Florida
Northwestern Memorial Hospital- Site Number : 8400043
Chicago, Illinois
University of Kansas Medical Center- Site Number : 8400045
Kansas City, Kansas
University of Michigan Health System - Ann Arbor- Site Number : 8400055
Ann Arbor, Michigan
Pulmonary and Medicine Associates- Site Number : 8400057
Warren, Michigan
Washington University- Site Number : 8400046
St Louis, Missouri
NYU Langone Medical Center- Site Number : 8400032
New York, New York
Southeastern Research Center- Site Number : 8400008
Winston-Salem, North Carolina
Clinical Research Associates of Central PA - Dubois- Site Number : 8400005
DuBois, Pennsylvania
Penn Medicine: University of Pennsylvania Health System- Site Number : 8400039
Philadelphia, Pennsylvania
Medical University of South Carolina - Charleston - Jonathan Lucas Street- Site Number : 8400027
Charleston, South Carolina
Metroplex Pulmonary and Sleep Center- Site Number : 8400014
McKinney, Texas
Pioneer Research Solutions, Inc.- Site Number : 8400048
Sugar Land, Texas
The University of Texas Health Center at Tyler- Site Number : 8400053
Tyler, Texas
Investigational Site Number : 0320003
Buenos Aires, Argentina
Investigational Site Number : 0320008
Buenos Aires, Argentina
Investigational Site Number : 0320001
Buenos Aires, Argentina
Investigational Site Number : 0320007
Córdoba, Argentina
Investigational Site Number : 0320006
Mendoza, Argentina
Investigational Site Number : 0320005
San Miguel de Tucumán, Argentina
Incor - Instituto do Coracao- Site Number : 0760002
São Paulo, Brazil
Hospital São Lucas da PUCRS - Porto Alegre - Avenida Ipiranga- Site Number : 0760001
Porto Alegre, Rio Grande do Sul, Brazil
WM Pesquisas Clínicas em Doenças Respiratórias- Site Number : 0760004
Porto Alegre, Rio Grande do Sul, Brazil
Investigational Site Number : 1240003
Guelph, Ontario, Canada
Investigational Site Number : 1240005
Sherbrooke, Quebec, Canada
Investigational Site Number : 1240001
Trois-Rivières, Quebec, Canada
Investigational Site Number : 1520001
Talca, Maule Region, Chile
Investigational Site Number : 1520003
Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 1520002
Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 1520004
Quillota, Valparaiso, Chile
Investigational Site Number : 1560005
Beijing, China
Showing 40 of 117 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.